30 closest matches · ranked by relevance
Atrial Arrhythmia · QT Interval, Variation in · Arrhythmias, Cardiac
Primary: QT Intervals During Antiarrhythmic Loading Hospitalization — 21.8 milliseconds
Stable Coronary Artery Disease (CAD) · Unstable Angina (Troponin Negative)
Primary: Mean Difference in QTc Interval Between ECG-2 and ECG-1 (ITT Population) — 0.94 milliseconds
Effects of Different Meals on the QT/QTc Interval · Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use · C-Peptide Effects on the QT/QTc Interval
Primary: The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin — 14.4; 11.6 ms — p=0.05
Metastatic Breast Cancer
Primary: Change From Baseline in Mean Duration of the QTc Interval — 1.2; -1.0; -4.0; -0.1 milliseconds
Prolonged QT Interval in EKG and Sudden Death
Primary: Baseline (Pre-Ibutilide) QTcI Intervals — 412; 419 ms — p=0.04
Long QT Syndrome
Primary: Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF) — 393; 399; 399 ms — p=0.09
Long QT Syndrome · Abnormalities, Drug-Induced
Primary: Baseline (Pre-ibutilide) QT-F Intervals — 417; 421; 413; 414 ms — p=0.07
Healthy
Primary: Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib — -1.62; -2.28 milliseconds
Healthy Volunteers
Primary: Change From Baseline in Electrocardiogram Results (QTcNi) at Time of Maximum Plasma Concentration (Tmax) on Day 1 — -3.37; 12.96; -0.94; -0.91 msec
QT Intervals Changes · QTc Intervals Changes
Primary: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part B — -2.6…
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Long QT Syndrome · Sleep Apnea
Primary: QT Interval (Corrected) Baseline Visit — 453.4 square root of seconds — p=0.73
Healthy
Primary: Mean Difference Changes From Baseline Versus Placebo in QTcNi Intervals From Time-Matched Analysis by Largest Time Point — 7.0; 13.0; 12.6 msec — p=<0.001
Healthy
Primary: Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 0.5 Hour Post-Dose — 404.09; 408.92…
Healthy
Primary: Change From Baseline in QTcF at That Timepoint Between 20 Minutes to 24 Hours After Drug Administration Where the Difference of Means in QTcF Changes From Baseline…
Advanced Solid Tumor
Primary: Mean Time-matched, Baseline Corrected QTcF at Any Time Point Postdosing. — 2; 11 msec
Jervell and Lange Nielsen Syndrome
Primary: QT Interval — 623 ms
Duchenne and Becker Muscular Dystrophy · Polycytemia Vera
Primary: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF) — 1.0; 0.5; 10.2; 0.3 Milliseconds (msec)
Anesthesia; Adverse Effect · Cardiac Arrhythmia
Primary: Change-from-baseline in QTc Interval — 2.1; 5.1; -0.1; 4.1 ms — p=<0.05
Cancer · Solid Tumor
Primary: Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants — 3.9132 milliseconds (msec) — p=0.0161
Long QT Syndrome · Cardiac Repolarization
Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms
Healthy Adult Subjects
Primary: Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186 — -0.5; 0.5 ms
Solid Cancers
Primary: Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State — -8.4 milliseconds (msec)
Bacterial Infections
Primary: Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 3; 2; 0 participants
Dyslipidemias
Primary: Change From Baseline in Fridericia's Correction for QT Interval (QTcF) — -4.6; 11.5; -6.0; -6.1 msec
Autoimmune Diseases
Primary: Change-from-baseline QT Interval Corrected for Heart Rate Using Fridericia's Method (QTcF) — 1.5; 0.9 msec
Healthy
Primary: Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose — 416.48; 417.77 milliseconds (msec)
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or…